ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
CG Oncology Inc

CG Oncology Inc (CGON)

28.76
-0.11
(-0.38%)
Closed December 14 4:00PM
28.76
-0.03
(-0.10%)
After Hours: 5:56PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
28.76
Bid
28.02
Ask
41.00
Volume
3,368,234
27.58 Day's Range 29.95
25.77 52 Week Range 50.23
Market Cap
Previous Close
28.87
Open
29.20
Last Trade
30
@
28.02
Last Trade Time
Financial Volume
$ 96,846,192
VWAP
28.7528
Average Volume (3m)
607,927
Shares Outstanding
67,629,675
Dividend Yield
-
PE Ratio
-28.72
Earnings Per Share (EPS)
-1
Revenue
204k
Net Profit
-67.8M

About CG Oncology Inc

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live ... CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Dover, Delaware, USA
Founded
-
CG Oncology Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CGON. The last closing price for CG Oncology was $28.87. Over the last year, CG Oncology shares have traded in a share price range of $ 25.77 to $ 50.23.

CG Oncology currently has 67,629,675 shares outstanding. The market capitalization of CG Oncology is $1.95 billion. CG Oncology has a price to earnings ratio (PE ratio) of -28.72.

CG Oncology (CGON) Options Flow Summary

Overall Flow

Bearish

Net Premium

-33k

Calls / Puts

0.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

CGON Latest News

CG Oncology Announces Pricing of Public Offering

IRVINE, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone...

CG Oncology Announces Proposed Public Offering

IRVINE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone...

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

SCHAUMBURG, Ill. and IRVINE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and...

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

– 74.5% of patients achieved a complete response at any time – – Median duration of response is greater than 27 months and not reached – – Latest data update continued to show favorable safety...

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024

IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone...

CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting

IRVINE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-5.13-15.137208616133.8935.4428.7653159932.03819466CS
4-6.7225-18.945959275735.482536.7328.7659512133.34786522CS
12-10.24-26.25641025643940.4728.7660792736.18236456CS
26-6.64-18.757062146935.440.4728.7661595735.32298608CS
52-0.24-0.8275862068972950.2325.7765321436.0552992CS
156-0.24-0.8275862068972950.2325.7765321436.0552992CS
260-0.24-0.8275862068972950.2325.7765321436.0552992CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WKEYWISeKey International Holdings AG
$ 7.84
(139.02%)
75.5M
IPHAInnate Pharma SA
$ 3.00
(93.55%)
13.59M
AVLDirexion Daily AVGO Bull 2X Shares
$ 33.67
(48.92%)
642.41k
LOOPLoop Industries Inc
$ 1.8092
(47.09%)
82.11M
AVGXDefiance Daily Target 2X Long AVGO ETF
$ 31.49
(46.67%)
3.42M
RPTXRepare Therapeutics Inc
$ 1.765
(-55.54%)
4.59M
INOInovio Pharmaceuticals Inc New
$ 2.31
(-38.56%)
9.59M
XXII22nd Century Group Inc
$ 0.048
(-34.69%)
41.72M
FLGCFlora Growth Corporation
$ 1.30
(-34.34%)
4.01M
WTOUTime Limited
$ 0.281
(-32.74%)
3.79M
NVDANVIDIA Corporation
$ 134.25
(-2.25%)
228.17M
SOUNSoundHound AI Inc
$ 16.905
(23.66%)
158.74M
TRUGTruGolf Holdings Inc
$ 0.6794
(30.93%)
138.19M
RGTIRigetti Computing Inc
$ 7.155
(19.85%)
122.67M
AVGOBroadcom Inc
$ 224.80
(24.43%)
117.74M

Your Recent History

Delayed Upgrade Clock